127 related articles for article (PubMed ID: 37749046)
1. [Ph-like B-cell acute lymphoblastic leukemia with ZEB2-JAK2 fusion gene positivity: a case report].
Shen K; Wang M; Hu DY; Guo YS; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Jul; 44(7):606. PubMed ID: 37749046
[No Abstract] [Full Text] [Related]
2. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
[TBL] [Abstract][Full Text] [Related]
3. Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia.
Zaliova M; Potuckova E; Lukes J; Winkowska L; Starkova J; Janotova I; Sramkova L; Stary J; Zuna J; Stanulla M; Zimmermann M; Bornhauser B; Bourquin JP; Eckert C; Cario G; Trka J
Haematologica; 2021 Mar; 106(3):886-890. PubMed ID: 32499245
[No Abstract] [Full Text] [Related]
4. Prognostic significance of CRLF2 overexpression and JAK2 mutation in Egyptian pediatric patients with B-precursor acute lymphoblastic leukemia.
Hassan NM; Abdellateif MS; Radwan EM; Hameed SA; Desouky EDE; Kamel MM; Gameel AM
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e376-e385. PubMed ID: 34987014
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma.
Peterson JF; Blackburn PR; Webley MR; Pearce KE; Williamson CM; Vasmatzis G; Smadbeck JB; Bieliauskas SL; Reichard KK; Ketterling RP; Baughn LB; Greipp PT
Mayo Clin Proc; 2019 Jul; 94(7):1381-1384. PubMed ID: 31272582
[No Abstract] [Full Text] [Related]
6. B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
Jaitly V; Wang W
Blood; 2018 Feb; 131(8):941. PubMed ID: 29472375
[No Abstract] [Full Text] [Related]
7. CRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.
Roll JD; Reuther GW
Cancer Res; 2010 Oct; 70(19):7347-52. PubMed ID: 20807819
[TBL] [Abstract][Full Text] [Related]
8. Detection of an atypical BCR::ABL1 fusion in a patient with secondary B-cell acute lymphoblastic leukemia/lymphoma following multiple myeloma treatment.
Miller K; Webster J; Imus P; Ament C; Hardy M; Zou YS
Cancer Genet; 2023 Jun; 274-275():30-32. PubMed ID: 36966724
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
Downes CEJ; Rehn J; Heatley SL; Yeung D; McClure BJ; White DL
Br J Haematol; 2022 Feb; 196(3):700-705. PubMed ID: 34697799
[TBL] [Abstract][Full Text] [Related]
10. JAK2 p.G571S in B-cell precursor acute lymphoblastic leukemia: a synergizing germline susceptibility.
Lin M; Nebral K; Gertzen CGW; Ganmore I; Haas OA; Bhatia S; Fischer U; Kuhlen M; Gohlke H; Izraeli S; Trka J; Hu J; Borkhardt A; Hauer J; Auer F
Leukemia; 2019 Sep; 33(9):2331-2335. PubMed ID: 30967616
[No Abstract] [Full Text] [Related]
11. Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis.
Herold T; Schneider S; Metzeler KH; Neumann M; Hartmann L; Roberts KG; Konstandin NP; Greif PA; Bräundl K; Ksienzyk B; Huk N; Schneider I; Zellmeier E; Jurinovic V; Mansmann U; Hiddemann W; Mullighan CG; Bohlander SK; Spiekermann K; Hoelzer D; Brüggemann M; Baldus CD; Dreyling M; Gökbuget N
Haematologica; 2017 Jan; 102(1):130-138. PubMed ID: 27561722
[TBL] [Abstract][Full Text] [Related]
12. ZEB2 in T-cells and T-ALL.
De Coninck S; Berx G; Taghon T; Van Vlierberghe P; Goossens S
Adv Biol Regul; 2019 Dec; 74():100639. PubMed ID: 31383581
[TBL] [Abstract][Full Text] [Related]
13. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
[TBL] [Abstract][Full Text] [Related]
14. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
Poitras JL; Dal Cin P; Aster JC; Deangelo DJ; Morton CC
Genes Chromosomes Cancer; 2008 Oct; 47(10):884-9. PubMed ID: 18618714
[TBL] [Abstract][Full Text] [Related]
15. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
[No Abstract] [Full Text] [Related]
16. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
17. Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
Mayfield JR; Czuchlewski DR; Gale JM; Matlawska-Wasowska K; Vasef MA; Nickl C; Pickett G; Ness SA; Winter SS
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27860260
[TBL] [Abstract][Full Text] [Related]
18. Disruption of E627 and R683 interaction is responsible for B-cell acute lymphoblastic leukemia caused by JAK2 R683G(S) mutations.
Wu QY; Guo HY; Li F; Li ZY; Zeng LY; Xu KL
Leuk Lymphoma; 2013 Dec; 54(12):2693-700. PubMed ID: 23452118
[TBL] [Abstract][Full Text] [Related]
19. The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.
Li F; Guo HY; Wang M; Geng HL; Bian MR; Cao J; Chen C; Zeng LY; Wang XY; Wu QY
Int J Biol Macromol; 2013 Sep; 60():186-95. PubMed ID: 23748007
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.
Goossens S; Peirs S; Van Loocke W; Wang J; Takawy M; Matthijssens F; Sonderegger SE; Haigh K; Nguyen T; Vandamme N; Costa M; Carmichael C; Van Nieuwerburgh F; Deforce D; Kleifeld O; Curtis DJ; Berx G; Van Vlierberghe P; Haigh JJ
Blood; 2017 Feb; 129(8):981-990. PubMed ID: 28069602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
